Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the shareholding of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on January 13, 2006:
- Previous Holding: 18,372,454 Ordinary Share ADRs
- New Holding: 18,409,914 Ordinary Share ADRs
- Average Price: $51.37
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a transaction under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the impact of the US Retirement Savings Plan's increased ADR holdings on total insider ownership percentages.
- Confirm the specific nature of the "fund movement" that triggered the share count adjustment.
- Review the full list of directors and connected persons to assess potential conflicts of interest regarding the Plan's holdings.